Significant Scientific Agreement Standard Could Be Revised Under McClellan
This article was originally published in The Tan Sheet
Executive Summary
FDA may revisit its significant scientific agreement standard for health claims, Commissioner Mark McClellan, MD/PhD, said at an American Enterprise Institute conference in Washington, D.C. Dec. 11